Full Text PAR-97-046 BEHAVIORAL SCIENCE TRACK AWARDS FOR RAPID TRANSITION-NIDA NIH GUIDE, Volume 26, Number 9, March 21, 1997 PA NUMBER: PAR-97-046 P.T. 34 Keywords: Behavioral/Social Studies/Service Psychology Social Psychology Drugs/Drug Abuse Cognitive Development/Process National Institute on Drug Abuse PURPOSE The National Institute on Drug Abuse (NIDA) invites newly independent investigators to submit applications for small-scale, exploratory (i.e., pilot) research projects related to NIDA's behavioral sciences mission. The Behavioral Science Track Award for Rapid Transition (B/START-NIDA) will provide rapid review and funding decisions of applications. Experimentally-based research applications are encouraged across a wide variety of behavioral factors in drug abuse, including neurocognitive, cognitive and perceptual processes, psychosocial, and more broadly motivational, social and community factors in drug abuse. Given the role that drug abuse plays in HIV/AIDS transmission, studies applying basic behavioral science models and methods to address this issue are especially encouraged. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Behavioral Science Track Awards for Rapid Transition-NIDA, is related to the priority area of alcohol and other drugs. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. To be eligible for a B/START-NIDA award, the proposed principal investigator must be independent of a mentor at the time of award but be at the beginning stages of her/his research career. If the applicant is in the final stages of training, he/she may apply, but no B/START award will be made to individuals in training status. The proposed principal investigator may not have been designated previously as principal investigator on any Public Health Service (PHS)-supported research project. Previous receipt of National Research Service Award funds (i.e., Institutional Training Grant or Individual Fellowship) is permissible. Foreign organizations are not eligible to apply. MECHANISM OF SUPPORT The funding mechanism that will be used to support this initiative is the small grant (R03). Each award is not to exceed $50,000 in direct costs and is for a period of one year only. The award is not renewable. RESEARCH OBJECTIVES The National Institute on Drug Abuse (NIDA), through the issuance of this Program Announcement (PA) hopes to facilitate the entry of beginning investigators into the field of behavioral science research. It is well-documented that the number of investigators entering basic behavioral sciences research is declining. This is of special concern to NIDA because understanding behavioral processes is fundamental to curbing drug abuse and addiction. Because of the importance of this public health mission, the pipeline of behavioral science investigators who will make the next important discoveries in drug abuse must not run dry. Recently NIDA has pursued several initiatives to emphasize its interest in the behavioral sciences. The purpose of this PA is to underscore NIDA's commitment and interest in expanding the scope of basic behavioral sciences research in drug abuse. NIDA supports both animal and human basic research to elucidate underlying behavioral mechanisms, determinants and correlates of drug abuse (both licit and illicit), and to characterize the harmful sequelae of drug abuse and addiction. Animal and human research applications are encouraged in the following broad areas (specific research examples shown are illustrative only; research topics will not be restricted to those listed). While the proposed project is not required to use drugs of abuse or to study drug abusers in the research protocol, the application should advance our understanding of and be related to drug abuse and addiction. o Behavioral genetic approaches either in animal models (e.g., transgenic animals, development of simple high-input behavioral screens) or human subject studies (e.g., establishment of pedigrees, twin studies). o Cognitive effects and causative factors (learning and memory, information processing, perceptual processes including pain and analgesia, attention, problem solving, concept formation, spatial ability, neuropsychology and neurocognition, animal cognition). o Psychosocial, social and personality factors (psychosocial risk factors, group and interpersonal processes, risk taking and HIV/AIDS, social influence, social values, social attitudes and cognition, persuasion conformity and compliance). o Motivational bases of behavior (self-control, behavioral alternatives, craving, appetitive and ingestive behaviors, emotion). INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95). Applications kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/710-0267, email: ASKNIH@odrockm1.od.nih.gov. The title and number of the program announcement must be typed in Section 2 on the face page of the application. The application length should not exceed 10 typewritten pages. Additionally, the new NIH Just-in-Time application procedures apply for B/START-NIDA submissions such that Other Support and detailed budgetary information is not required until the application is likely to be funded. See the NIH Guide for Grants and Contracts, Volume 25, Number 10, March 29, 1996 for further information. The completed original application and three legible copies must be sent or delivered to: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20897 (if using courier/express service) To permit an expedited review of the application, applicants must simultaneously send two complete copies to: Office of Extramural Program Review National Institute on Drug Abuse 5600 Fishers Lane, Room 10-42 Rockville, MD 20857 In FY 97, the regular receipt date of June 1 for R03 applications applies. For FY 98 and beyond, there will be two receipt dates per fiscal year: October 1 and February 1. REVIEW CONSIDERATIONS Applications that are complete and responsive to the program announcement will be evaluated for scientific and technical merit by appropriate peer reviewers. As part of the merit review, all applications will receive a written critique. Scientific reviews will be conducted on receipt of the application. In about five months, applicants will be notified by NIDA staff whether or not their application will be funded. No funding will occur during the months of October and November. Revised B/START- NIDA applications are not allowed. Review Criteria o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o availability of the resources necessary to perform the research; o adequacy of plans to include both genders and minorities as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The reviewers will also examine the provisions for the protection of human and animal subjects, and the safety of the research environment. AWARD CRITERIA It is anticipated that up to $500,000 for FY 1997 will be available to support projects submitted under this program announcement. Future years' support will depend upon available appropriations. The following will be considered in making funding decisions: Quality of the proposed project as determined by peer review, availability of funds, and program priority. INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Jaylan Turrkan, Ph.D. Division of Basic Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A31 Rockville, MD 20857 Telephone: (301) 443-1263 Email: jaylan@helix.nih.gov Harold Gordon, Ph.D. Division of Clinical and Services Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A-46 Rockville, MD 20857 Telephone: (301) 443-4877 Email: hg23r@nih.gov Meyer Glantz, Ph.D. Division of Epidemiology and Prevention Research National Institute on Drug Abuse 5600 Fishers Lane, Room 9A-55 Rockville, MD 20857 Telephone: (301) 4432974 Email: mg115g@nih.gov Direct inquiries regarding fiscal matters to: Dr. Gary Fleming Grants Management Branch National Institute on Drug Abuse 5600 Fishers Lane, Room 8A-54 Rockville, MD 20857 Telephone: (301) 443-6710 Email: gf6s@nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.279. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The Public Health Service (PHS) strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro- Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |